# US 2024/0199563 A1 · Antimicrobial and anticancer agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199563 A1
- Document ID: US20240199563A1
- Status: Published application
- Kind: A1
- Application number: 18/556,480
- Filed: 2022-04-28
- Published: 2024-06-20
- Earliest claimed: 2021-04-29
- Assignees: Geistlich Pharma AG
- Applicants: Geistlich Pharma AG
- Inventors: Thomas Mueller; Hanns Moehler; James C. Costin
- Web page: https://patentgrep.com/patent/US20240199563A1

## CPC

- C07D 291/06: Six-membered rings
- A61K 31/549: having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formula (I) useful as antineoplastic and antimicrobial agents are disclosed Compositions and methods of using antineoplastic and antimicrobial compounds are disclosed.

## Claims

### Claim 1

A compound selected from:
a compound of Formula I:
wherein R1 is —CO-aryl and R2 is H;

### Claim 2 (depends on 1)

A pharmaceutical composition comprising at least one compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein said composition is in the form of an orally administrable composition.

### Claim 4 (depends on 2)

The pharmaceutical composition of claim 2, wherein said composition is in the form of a capsule, a tablet, or a pharmaceutically acceptable solution.

### Claim 5 (depends on 2)

The pharmaceutical composition of claim 2, wherein said composition contains the compound at a concentration of about 0.01 to about 3% w/v.

### Claim 6 (depends on 2)

The pharmaceutical composition of claim 2, wherein said composition contains the compound at a concentration of about 0.01 to about 1000 μg/ml.

### Claim 7 (depends on 2)

The pharmaceutical composition of claim 2, wherein said composition contains one or more solubilizing agents.

### Claim 8 (depends on 2)

The pharmaceutical composition of claim 2, wherein said composition comprises a polyol.

### Claim 9 (depends on 2)

The pharmaceutical composition of claim 2, wherein said composition is an injection and/or infusion formulation comprising a pharmaceutically acceptable injection or infusion carrier.

### Claim 10 (depends on 1)

An oral dosage form comprising at least one compound of claim 1.

### Claim 11 (depends on 1)

A method of treating a subject suffering from cancer comprising administering to said subject the compound of claim 1.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cancer is glioblastoma, glioma, neuroblastoma, astrocytoma, carcinomatous meningitis, colon cancer, rectal cancer, colorectal cancer, ovarian cancer, breast cancer, prostate cancer, lung cancer, mesothelioma, melanoma, renal cancer, liver cancer, pancreatic cancer, gastric cancer, esophageal cancer, urinary bladder cancer, cervical cancer, cardiac cancer, gall bladder cancer, skin cancer, bone cancer, cancers of the head and neck, leukemia, lymphoma, lymphosarcoma, adenocarcinoma, fibrosarcoma, or a metastasis thereof.

### Claim 13 (depends on 1)

A method of treating a subject suffering from a microbial infection comprising administering to said subject the compound of claim 1.

### Claim 14 (depends on 1)

A method of treating tumor stem cells in a subject comprising administering to said subject the compound of claim 1.

### Claim 15 (depends on 1)

A method of treating a subject in need of anti-angiogenesis comprising administering to said subject the compound of claim 1.

### Claim 16 (depends on 1)

A method of treating a subject in need of anti-tubulogenesis comprising administering to said subject the compound of claim 1.

### Claim 17 (depends on 1)

A method of treating a subject suffering from a bacterial infection comprising administering to said subject the compound of claim 1.

### Claim 18 (depends on 1)

A method of treating a subject suffering from a viral infection comprising administering to said subject the compound of claim 1.

### Claim 19 (depends on 1)

A method of providing a co-therapeutic regimen to a subject, comprising administering taurolidine and/or taurultam in combination with at least one compound of claim 1, as a co-therapy to the subject.

### Claim 20 (depends on 1)

A method of broadening the pharmacokinetic effects of taurolidine and/or taurultam in a human subject using at least two compounds having different half-lives, comprising administering to the human subject taurolidine and/or taurultam in combination with at least one compound of claim 1.

### Claim 21 (depends on 19)

The method of claim 19, wherein said method comprises administering a dosage of 0.1-1,000 mg/kg of said at least one compound in combination with a dosage of 0.01-500 mg/kg of taurolidine and/or taurultam.

### Claim 22 (depends on 19)

The method of claim 19, wherein said method comprises administering a total daily dose of about 0.1 g to about 100 g of said at least one compound in combination with a total daily dose of about 0.01 g to about 50 g of taurolidine and/or taurultam.

### Claim 23 (depends on 1)

A method of providing a co-therapeutic regimen to a subject, comprising administering a) at least one compound of claim 1, as a co-therapy to the subject with b) carmustine, cytarabine, gemcitabine, nabPaclitaxel, asparaginase, procarbazine, mitomycin, 5-FU, methotrexate, vinblastine, dacarbazine, cisplatin, carboplatin, paclitaxel, bevacizumab, one or more checkpoint inhibitors, one or more PARP inhibitors, one or more anti-PD-1 drugs, docetaxel, irinotecan (including Onivyde®), doxorubicin, erlotinib, olaparib, lapatinib, topotecan, capecitabine, oxaliplatin, cyclophosphamide, ifosfamide, or a combination thereof.
